\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a “Know the User” event today, October 24, 2022, at its new CLIA Bionano labs. -certified center before the 2022 annual meeting of the American Society for Human Genetics (ASHG). The occasion is the first assembly of clinical users in the company’s history to bring together researchers curious about optical genome mapping (GMO) and revel in users, enabling hands-on experiments and hands-on delight with other facets of the GMO workflow, adding pattern selection, DNA isolation, tagging, knowledge gathering and reporting. More than 50 Bionano consumers and customers from countries including Canada, France, Lebanon, Sweden, Germany, India and Mexico will gather for constitutional, hematological and cellular biotreatment case presentations, demonstrations of Bionano’s Saphyr® System and NxClinical™ software and user groups.
The day’s schedule will come with an excursion to Bionano’s labs, with a hands-on demonstration of the GMO workflow through expert technologists and technologists. a scholar at the Greenwood Genetic Center, will lead educational sessions aimed at analyzing knowledge about rare undiagnosed diseases and instances of hematologic malignancies. their experience and approaches to implementing GMOs in their laboratories for various study programs that read genetic diseases. Bionano’s chief operating officer, Mark Oldakowski, will also provide a review of the company’s product roadmap.
“Our user assembly is a wonderful opportunity to introduce Bionano Laboratories to our interested consumers and prospects. The day’s schedule will come with practical data and real-life usage instances from our on-site GMO experts and visiting GMO users, as well as a discussion of study issues and networking opportunities. This occasion is a milestone for Bionano and demonstrates the increased adoption and interest in GMOs worldwide,” commented Dr. Anna Stuart. Alka Chaubey, Medical Director of Bionano Genomics.
“Bionano is pleased to host its first-ever ‘Know the User’ event, which will bring together clinical leaders who pioneered the use of GMOs and researchers interested in being more informed about how our generation of GMOs can their studies through unraveling genomic aberrations related to a genetic disease. The reaction to this occasion was tremendous, with more than fifty participants coming from countries around the world. We anticipate detailed case presentations, demonstrations of the Saphyr System in our new CLIA-certified laboratory, and the opportunity for researchers to be informed of each other,” said Erik Holmlin, president and CEO of Bionano.
About Bionano Genomics
Bionano Genomics is a provider of genome research answers that can enable researchers and clinicians to reveal answers to difficult questions in biology and medicine. The company’s project is how global genome perspectives through GMO responses, diagnostic facilities and software. The GMO company responds to basic, translational and clinical research programs. Through its company Lineagen, Inc. d/b/a Bionano Laboratories, the company also provides diagnostic tests to patients with clinical presentations compatible with autism spectrum disorders and other neurodevelopmental disorders. BioDiscovery, the company also offers a next-generation platform-agnostic software solution that integrates next-generation microarray and DNA sequencing expertise designed to provide investigation, visualization, interpretation, and reporting of copy number, single-nucleotide variants, and genome-wide heterozygosity in a consolidated view. For more information, visit www. bionanogenomics. com, www. bionanolaboratories. com or www. biodiscovery. com
Bionano Genomics Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “possibly” and similar expressions (as well as other words or expressions that refer to long-term occasions, situations or term) convey uncertainty about the long term. occasions or effects and are intended to identify such forward-looking statements. Forward-looking statements come with statements regarding our intentions, beliefs, projections, prospects, analyzes or existing expectations related to, among other things, the usefulness of GMOs in helping researchers get to the bottom of disease-related genomic aberrations. genetics. Each of these forward-looking statements involves dangers and uncertainties. Actual effects or developments may differ materially from those projected or implied by such forward-looking statements. Factors that may also cause such a difference come with risks and uncertainties related to: the effect of the COVID-19 pandemic on our business and the global economy; general market situations; adjustments in the competitive landscape and the advent of competitive technologies or improvements to existing technologies; the failure of GMOs to achieve an application that helps get to the bottom of genomic aberrations related to genetic diseases; adjustments to our strategic and business plans; our ability to offload sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research establishments to offload investments to aid the continued adoption or use of our technologies; and the dangers and uncertainties relating to our business and monetary condition in general, adding the dangers and uncertainties described in our filings with the Securities and Exchange Commission, including, among others, our annual report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently filed through us with the Securities and Exchange Commission. All forward-looking statements in this press release speak only as of the date they are made and are based on management’s assumptions and estimates as of that date. We assume no legal responsibility to publicly update any forward-looking statement, whether as a result of the receipt of new information, the occurrence of long-term events or otherwise.
CONTACTSContact:Erik Holmlin, PDGBionano Genomics, Inc. 1 (858) 888-7610eholmlin@bionanogenomics. com
Investor Relations:Amy ConradJuniper Point 1 (858) 366-3243amy@juniper-point. com